{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,18]],"date-time":"2026-07-18T16:13:44Z","timestamp":1784391224326,"version":"3.55.0"},"reference-count":28,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2022,4,1]],"date-time":"2022-04-01T00:00:00Z","timestamp":1648771200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,4,1]],"date-time":"2022-04-01T00:00:00Z","timestamp":1648771200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,4,1]],"date-time":"2022-04-01T00:00:00Z","timestamp":1648771200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2022,4,1]],"date-time":"2022-04-01T00:00:00Z","timestamp":1648771200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2022,4,1]],"date-time":"2022-04-01T00:00:00Z","timestamp":1648771200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2022,4,1]],"date-time":"2022-04-01T00:00:00Z","timestamp":1648771200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2022,4,1]],"date-time":"2022-04-01T00:00:00Z","timestamp":1648771200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","clinical-lymphoma-myeloma-leukemia.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Lymphoma Myeloma and Leukemia"],"published-print":{"date-parts":[[2022,4]]},"DOI":"10.1016\/j.clml.2021.09.017","type":"journal-article","created":{"date-parts":[[2021,9,29]],"date-time":"2021-09-29T17:46:57Z","timestamp":1632937617000},"page":"251-259","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":4,"title":["Outcomes of HTLV-1 Carriers with Diffuse Large B-Cell Lymphoma: A Single-Center Retrospective Matched Cohort Study"],"prefix":"10.1016","volume":"22","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-3853-2603","authenticated-orcid":false,"given":"Bryan","family":"Valcarcel","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gustavo Sandival","family":"Ampuero","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4203-3890","authenticated-orcid":false,"given":"Gabriel","family":"de la Cruz-Ku","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0855-8936","authenticated-orcid":false,"given":"Daniel J","family":"Enriquez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7082-1846","authenticated-orcid":false,"given":"Luis","family":"Malpica","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.clml.2021.09.017_bib0001","doi-asserted-by":"crossref","first-page":"388","DOI":"10.3389\/fmicb.2012.00388","article-title":"Epidemiological aspects and world distribution of HTLV-1 infection","volume":"3","author":"Gessain","year":"2012","journal-title":"Front Microbiol"},{"key":"10.1016\/j.clml.2021.09.017_bib0002","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1016\/j.coviro.2017.07.013","article-title":"The impact of HTLV-1 on the cellular genome","volume":"26","author":"Cook","year":"2017","journal-title":"Curr Opin Virol"},{"key":"10.1016\/j.clml.2021.09.017_bib0003","doi-asserted-by":"crossref","first-page":"607","DOI":"10.1182\/bloodadvances.2017011106","article-title":"Epidemiology, clinical features, and outcome of HTLV-1-related ATLL in an area of prevalence in the United States","volume":"2","author":"Malpica","year":"2018","journal-title":"Blood Adv"},{"key":"10.1016\/j.clml.2021.09.017_bib0004","doi-asserted-by":"crossref","first-page":"2570","DOI":"10.1182\/blood-2015-03-632489","article-title":"Treatment and survival among 1594 patients with ATL","volume":"126","author":"Katsuya","year":"2015","journal-title":"Blood"},{"key":"10.1016\/j.clml.2021.09.017_bib0005","doi-asserted-by":"crossref","first-page":"889","DOI":"10.1023\/B:CACO.0000003853.82298.96","article-title":"Human T-lymphotropic virus type-I infection, survival and cancer risk in southwestern Japan: a prospective cohort study","volume":"14","author":"Arisawa","year":"2003","journal-title":"Cancer causes & control: CCC"},{"key":"10.1016\/j.clml.2021.09.017_bib0006","series-title":"World Cancer Report: Cancer research for cancer prevention Lyon","year":"2020"},{"key":"10.1016\/j.clml.2021.09.017_bib0007","doi-asserted-by":"crossref","first-page":"12168","DOI":"10.1038\/srep12168","article-title":"Epstein-Barr virus positive diffuse large B-cell lymphoma predict poor outcome, regardless of the age","volume":"5","author":"Lu","year":"2015","journal-title":"Sci Rep"},{"key":"10.1016\/j.clml.2021.09.017_bib0008","doi-asserted-by":"crossref","first-page":"1170","DOI":"10.1111\/cas.12467","article-title":"Clinical outcome of Epstein-Barr virus-positive diffuse large B-cell lymphoma of the elderly in the rituximab era","volume":"105","author":"Sato","year":"2014","journal-title":"Cancer Sci"},{"key":"10.1016\/j.clml.2021.09.017_bib0009","doi-asserted-by":"crossref","first-page":"2493","DOI":"10.1097\/QAD.0000000000001652","article-title":"Outcomes for HIV-associated diffuse large B-cell lymphoma in the modern combined antiretroviral therapy era","volume":"31","author":"Besson","year":"2017","journal-title":"AIDS"},{"key":"10.1016\/j.clml.2021.09.017_bib0010","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1093\/jnci\/89.4.301","article-title":"Opportunistic infection and immunologic function in patients with human immunodeficiency virus-associated non-Hodgkin's lymphoma treated with chemotherapy","volume":"89","author":"Sparano","year":"1997","journal-title":"J Natl Cancer Inst"},{"key":"10.1016\/j.clml.2021.09.017_bib0011","doi-asserted-by":"crossref","first-page":"857","DOI":"10.3324\/haematol.2017.180893","article-title":"Incidence and risk factors for relapses in HIV-associated non-Hodgkin lymphoma as observed in the German HIV-related lymphoma cohort study","volume":"103","author":"Schommers","year":"2018","journal-title":"Haematologica"},{"key":"10.1016\/j.clml.2021.09.017_bib0012","doi-asserted-by":"crossref","first-page":"606","DOI":"10.1046\/j.1365-2141.2003.04653.x","article-title":"HTLV-1 carriers with B-cell lymphoma of localized stage head and neck: prognosis, clinical and immunopathological features","volume":"123","author":"Suefuji","year":"2003","journal-title":"Br J Haematol"},{"key":"10.1016\/j.clml.2021.09.017_bib0013","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1186\/1750-9378-4-10","article-title":"EBV-positive diffuse large B-cell lymphoma in a human T-lymphotropic virus type 1 carrier","volume":"4","author":"Beltran","year":"2009","journal-title":"Infectious agents and cancer"},{"key":"10.1016\/j.clml.2021.09.017_bib0014","doi-asserted-by":"crossref","DOI":"10.1155\/2012\/262363","article-title":"Diffuse large B-cell lymphoma in human T-lymphotropic virus type 1 carriers","volume":"2012","author":"Beltran","year":"2012","journal-title":"Leukemia research and treatment"},{"key":"10.1016\/j.clml.2021.09.017_bib0015","doi-asserted-by":"crossref","first-page":"837","DOI":"10.1182\/blood-2013-09-524108","article-title":"An enhanced International Prognostic Index (NCCN-IPI) for patients with diffuse large B-cell lymphoma treated in the rituximab era","volume":"123","author":"Zhou","year":"2014","journal-title":"Blood"},{"key":"10.1016\/j.clml.2021.09.017_bib0016","doi-asserted-by":"crossref","first-page":"3059","DOI":"10.1200\/JCO.2013.54.8800","article-title":"Recommendations for initial evaluation, staging, and response assessment of Hodgkin and non-Hodgkin lymphoma: the Lugano classification","volume":"32","author":"Cheson","year":"2014","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.clml.2021.09.017_bib0017","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1182\/blood-2003-05-1545","article-title":"Confirmation of the molecular classification of diffuse large B-cell lymphoma by immunohistochemistry using a tissue microarray","volume":"103","author":"Hans","year":"2004","journal-title":"Blood"},{"key":"10.1016\/j.clml.2021.09.017_bib0018","doi-asserted-by":"crossref","first-page":"3183","DOI":"10.1182\/blood-2005-04-1399","article-title":"Diffuse large B-cell lymphoma subgroups have distinct genetic profiles that influence tumor biology and improve gene-expression-based survival prediction","volume":"106","author":"Bea","year":"2005","journal-title":"Blood"},{"key":"10.1016\/j.clml.2021.09.017_bib0019","doi-asserted-by":"crossref","first-page":"3359","DOI":"10.1200\/JCO.19.00743","article-title":"Prognostic Significance of MYC Rearrangement and Translocation Partner in Diffuse Large B-Cell Lymphoma: A Study by the Lunenburg Lymphoma Biomarker Consortium","volume":"37","author":"Rosenwald","year":"2019","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.clml.2021.09.017_bib0020","doi-asserted-by":"crossref","first-page":"604","DOI":"10.1002\/ajh.25460","article-title":"Diffuse large B-cell lymphoma: 2019 update on diagnosis, risk stratification, and treatment","volume":"94","author":"Liu","year":"2019","journal-title":"Am J Hematol"},{"key":"10.1016\/j.clml.2021.09.017_bib0021","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1016\/j.pathol.2017.09.006","article-title":"Diffuse large B-cell lymphoma","volume":"50","author":"Li","year":"2018","journal-title":"Pathology"},{"key":"10.1016\/j.clml.2021.09.017_bib0022","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1038\/35000501","article-title":"Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling","volume":"403","author":"Alizadeh","year":"2000","journal-title":"Nature"},{"key":"10.1016\/j.clml.2021.09.017_bib0023","doi-asserted-by":"crossref","first-page":"5573","DOI":"10.1200\/JCO.2009.22.7058","article-title":"Immuno-fluorescence in situ hybridization index predicts survival in patients with diffuse large B-cell lymphoma treated with R-CHOP: a GELA study","volume":"27","author":"Copie-Bergman","year":"2009","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.clml.2021.09.017_bib0024","doi-asserted-by":"crossref","first-page":"3360","DOI":"10.1200\/JCO.2009.26.3947","article-title":"Rearrangement of MYC is associated with poor prognosis in patients with diffuse large B-cell lymphoma treated in the era of rituximab","volume":"28","author":"Barrans","year":"2010","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.clml.2021.09.017_bib0025","doi-asserted-by":"crossref","first-page":"3460","DOI":"10.1200\/JCO.2011.41.4342","article-title":"Immunohistochemical double-hit score is a strong predictor of outcome in patients with diffuse large B-cell lymphoma treated with rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone","volume":"30","author":"Green","year":"2012","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.clml.2021.09.017_bib0026","doi-asserted-by":"crossref","first-page":"e609","DOI":"10.1016\/S2352-3026(18)30177-7","article-title":"Dose-adjusted EPOCH-R (etoposide, prednisone, vincristine, cyclophosphamide, doxorubicin, and rituximab) in untreated aggressive diffuse large B-cell lymphoma with MYC rearrangement: a prospective, multicenter, single-arm phase 2 study","volume":"5","author":"Dunleavy","year":"2018","journal-title":"Lancet Haematol"},{"key":"10.1016\/j.clml.2021.09.017_bib0027","doi-asserted-by":"crossref","first-page":"520","DOI":"10.1159\/000505892","article-title":"The spectrum of MYC alterations in diffuse large B-Cell Lymphoma","volume":"143","author":"Xia","year":"2020","journal-title":"Acta Haematol"},{"key":"10.1016\/j.clml.2021.09.017_bib0028","first-page":"485","article-title":"HTLV-1 infection: An emerging risk. Pathogenesis, epidemiology, diagnosis and associated diseases","volume":"32","author":"Eusebio-Ponce","year":"2019","journal-title":"Rev Esp Quimioter"}],"container-title":["Clinical Lymphoma Myeloma and Leukemia"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2152265021020693?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2152265021020693?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,31]],"date-time":"2025-10-31T00:38:16Z","timestamp":1761871096000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2152265021020693"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,4]]},"references-count":28,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2022,4]]}},"alternative-id":["S2152265021020693"],"URL":"https:\/\/doi.org\/10.1016\/j.clml.2021.09.017","relation":{},"ISSN":["2152-2650"],"issn-type":[{"value":"2152-2650","type":"print"}],"subject":[],"published":{"date-parts":[[2022,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Outcomes of HTLV-1 Carriers with Diffuse Large B-Cell Lymphoma: A Single-Center Retrospective Matched Cohort Study","name":"articletitle","label":"Article Title"},{"value":"Clinical Lymphoma Myeloma and Leukemia","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clml.2021.09.017","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}